$27.1M in expenses

The PCF research enterprise is a peer-review research funding program that provides funding to 2,250 scientists conducting innovative research projects at more than 245 leading cancer centers and universities. Priority is given to high-risk, high-return projects with the greatest potential to improve survival and the overall quality of life for men with prostate cancer. The cornerstone of the PCF research enterprise in 2024 was our challenge awards program and new tactical awards program, which support cross-disciplinary teams of investigators conducting pioneering research to address critical unmet medical needs for prostate cancer patients. In 2024, PCF funded 15 multi-year team research projects that each offer high potential for improved detection, enhanced quality of life and higher survival rates.

$15.8M in expenses

For more than 3 million american men and their families fighting prostate cancer and millions more globally, PCF serves as a primary source for new standard-of-care and research information. PCF educates the public about prostate cancer risks, screening, prevention, treatment options, and side effects. We connect patients, loved ones, care providers, and scientists to critical updates, the latest developments, best practices, and news from the treatment pipeline. Since PCF's inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF aims to spur men and women alike to talk about this disease, to understand its urgency, and to have information-driven hope.

$6.2M in expenses

PCF created the young investigator award program with one goal: to build a gifted cohort of human capital supporting the next generation of prostate cancer researchers. Awards are made to early-career scientists working in a research environment capable of supporting high-impact prostate cancer research, drawn from a variety of medical research disciplines. In its 27th year, the PCF program has awarded nearly $93 million to advance the careers of 435 PCF young investigators, ensuring a continued stream of human capital into our research community. The PCF young investigator program plays an integral role in championing, mentoring, and identifying future medical research program leaders.

$1.0M in expenses

More than 12,000 men cared for by the department of veterans affairs (VA) hospitals are newly diagnosed with prostate cancer each year, making it the most frequently diagnosed cancer among veterans. The PCF-VA partnership is expanding research into prostate cancer precision oncology treatment options. The collaboration is expanding the number of precision oncology clinical studies conducted at veterans health administration hospitals, ensuring that eligible veterans can access and participate in these studies. The VA's precision oncology program for cancer of the prostate (popcap) was established in partnership with the prostate cancer foundation 2016. The program uses genetic testing to find the best possible treatments for veterans with advanced prostate cancer. Popcap's network extends across the u.s. It includes 21 precision oncology centers of excellence, supplemented by regional centers, that provide cancer care to any veteran who develops prostate cancer, no matter where he lives.